Table 5

Association between nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer according to stage, National Institutes of Health–AARP Study

In situ breast cancer
 Invasive breast cancer

NSAID use
 Number of cancers
 Person-years
 Relative riska
 95% confidence interval
 P value for trend
 Number of cancers
 Person-years
 Relative riska
 95% confidence interval
 P value for trend
Aspirin useb









     Never
 298
 280,077
 1.00 (referent)
0.02
 1,254
 283,247
 1.00 (referent)
0.37
     <1/week
 233
 261,641
 0.80
 0.67 to 0.96
1,166
 264,821
 0.99
 0.91 to 1.07
     1–6/week
 124
 131,305
 0.85
 0.69 to 1.05
589
 132,899
 0.98
 0.88 to 1.08
     1+/day
 122
 143,137
 0.78
 0.63 to 0.96
648
 144,854
 0.96
 0.87 to 1.06
Non-aspirin NSAID useb









     Never
 292
 324,890
 1.00 (referent)
0.45
 1,463
 328,884
 1.00 (referent)
0.88
     <1/week
 269
 258,097
 1.14
 0.96 to 1.35
1,140
 261,013
 0.97
 0.90 to 1.05
     1–6/week
 122
 124,433
 1.06
 0.85 to 1.31
569
 125,934
 1.01
 0.92 to 1.12
     1+/day
 91
 107,466
 0.87
 0.69 to 1.10
494
 108,757
 0.98
 0.89 to 1.09

aAdjusted for age (continuous), race, age at first birth, hormone therapy use, number of breast biopsies, alcohol intake, history of hypertension, and family history of breast cancer in first-degree relative.

bThese models also include terms for frequency of use of opposite NSAID type.

Gierach et al. Breast Cancer Research 2008 10:R38   doi:10.1186/bcr2089